Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane

Park, Sung Min; Lee, Jeong Eon; Yu, Jonghan; Paik, Hyun-June; Ryu, Jai Min; Kim, Isaac; Bae, Soo Youn; Lee, Se Kyung; Kim, Seok Won; Nam, Seok Jin; Kim, Eun‐Kyu; Kang, Eunyoung; Yang, Eun Joo

doi:10.1016/j.clbc.2017.06.003

Cited by 18 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no significant differences between the two groups in any demographic (age, BMI, and weight) or breast cancer-related characteristics (affected site, pathological stage group, recurrence, surgery method, number of dissected lymph nodes, time since first breast cancer surgery, and administration of radiotherapy and chemotherapy). Patients who received radiotherapy and chemotherapy were administrated with radiotherapy according to their clinical stage followed by neoadjuvant systemic chemotherapy (NAC) [29].…”

Section: Resultsmentioning

confidence: 99%

Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System

2019

Self Cite

View full text Add to dashboard Cite

Long-term surveillance is necessary to identify patients at risk of developing secondary lymphedema after breast cancer surgery. We assessed how sodium selenite supplementation would affect breast cancer-related lymphedema (BCRL) symptoms and parameters in association with antioxidant effects. A randomized, double-blind, controlled trial was conducted on 26 participants with clinical stage II to III BCRL. The control group (CTRL, n = 12) and selenium group (SE, n = 14) underwent five sessions of 0.9% saline and 500 μg sodium selenite (Selenase®) IV injections, respectively, within 2 weeks. All patients were educated on recommended behavior and self-administered manual lymphatic drainage. Clinical diagnosis on lymphedema by physicians, bioimpedance data, blood levels of oxidative markers, including glutathione (GSH), glutathione disulfide (GSSG), malondialdehyde (MDA), glutathione peroxidase activity (GSH-Px), and serum oxygen radical absorbance capacity (ORAC) levels, were investigated at timelines defined as baseline, 2-week, and follow-up. Sodium selenite increased whole blood selenium concentration in the SE group. Compared to the baseline, at 2 weeks, 75.0% of participants in clinical stage showed improvement, while there was no change in the CTRL group. At follow-up, 83.3% and 10.0% of the SE and CTRL, respectively, showed stage changes from III to II (p = 0.002). Extracellular water (ECW) ratios were significantly reduced at 2 weeks and follow-up, only in the SE group. Blood GSH, GSSG, GSH/GSSG ratio, MDA, and ORAC levels did not change by selenium supplementation. Sodium selenite improved diagnostic stages of BCRL along with ECW ratios, although the beneficial effect might not be related to its antioxidant activity. Selenite’s effect on lymphedema may be associated with non-antioxidant properties, such as anti-inflammation and immune function. Further mechanistic research using a larger population is needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Table 3 shows the results of a multivariable regression model includ- Numerous studies have identified elevated BMI as an important risk factor in this context (Can et al, 2016;DiSipio et al, 2013;Duyur Caklt et al, 2019;Leray et al, 2020;Park et al, 2018;Rastogi et al, 2018;Tsai et al, 2020;Winkels et al, 2017), and it has been specifically associated with increased swelling of the affected arm (Rastogi et al, 2018) and an almost twofold higher risk of BCRL (Chooi et al, 2019). In the study by Park et al, (2018), BMI ≥ 25 kg/m 2 was an independent risk factor for lymphoedema in an analysis of 406 women who received neoadjuvant chemotherapy prior to surgery. In relation to the management of BCRL, Tsai et al, (2020), in a systematic review of 461 studies, concluded that weight reduction significantly reduced the volume of the affected and unaffected arms.…”

Section: Prediction Model For the Risk Of Lymphoedemamentioning

confidence: 99%

Breast cancer‐related lymphoedema: Risk factors and prediction model

Martínez-Jaimez

Verdú

Forero

et al. 2021

Journal of Advanced Nursing

View full text Add to dashboard Cite

Aims: To identify the risk factors for lymphoedema following axillary lymph node dissection (ALND) in a European sample and to propose a lymphoedema prediction model for this population. Design: Predictive retrospective cohort study comparing women who developed lymphoedema in 2 years of undergoing ALND with those who did not developed lymphoedema. Methods: We reviewed the clinical records of 504 women who, between January 2008 and May 2018, underwent surgery for breast cancer that involved ALND. Logistic regression was used to identify significant risk factors for lymphoedema. The prediction accuracy of the model was assessed by calculating the area under the receiver operating characteristic curve. Results: Of the 504 women whose records were analysed, 156 developed lymphoedema. Significant predictors identified in the regression model were level of lymph node dissection, lymph node status, post-operative complications, body mass index (BMI) and number of lymph nodes extracted. The prediction model showed good sensitivity (80%) in the study population. Conclusions:The factor contributing most to the risk of lymphoedema was the level of lymph node dissection, and the only patient-related factor in the prediction model was BMI. The model offers good predictive capacity in this population and it is a simple tool that breast care units could use to assess the risk of lymphoedema following ALND. Nurses with specialist knowledge of lymphoedema have a key role to play in ensuring that women receive holistic and individualized care.

show abstract

“…1 The average incidence of secondary lymphedema in women following breast cancer treatment is 20%, 2,3 and with a number of studies reporting an increased incidence of up to 60%. [4][5][6] These numbers indicate that lymphedema is one of the most pressing survivorship issues among women who have been treated for breast cancer, though sustainable treatment options remain elusive.…”

Section: Introductionmentioning

confidence: 99%

“…Lymphedema is a common complication in cancer survivors with an overall incidence of 15.5%, and increased risk among patients who undergo pelvic dissections (22%) or radiation therapy (31%) 1 . The average incidence of secondary lymphedema in women following breast cancer treatment is 20%, 2,3 and with a number of studies reporting an increased incidence of up to 60% 4–6 . These numbers indicate that lymphedema is one of the most pressing survivorship issues among women who have been treated for breast cancer, though sustainable treatment options remain elusive.…”

Section: Introductionmentioning

confidence: 99%

Lymphatic regeneration after implantation of aligned nanofibrillar collagen scaffolds: Preliminary preclinical and clinical results

Nguyen

Zaitseva

Zhou

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: We tested our hypothesis that implantation of aligned nanofibrillar collagen scaffolds (BioBridge™) can both prevent and reduce established lymphedema in the rat lymphedema model. Our authors report clinical cases that demonstrate new lymphatic formation guided by BioBridge™ as seen by near-infrared (NIR) fluoroscopy and magnetic resonance (MR) lymphography. Methods: A rat lymphedema model was utilized. A prevention group received implantation of BioBridge™ immediately after lymphadenectomy. A lymphedema group received implantation of BioBridge™ with autologous adipose-derived stem cells (ADSC; treatment group) or remained untreated (control group). All subjects were observed for 4 months after lymphadenectomy. The hindlimb change was evaluated using computed tomography-based volumetric analysis. Lymphagiogenesis was assessed by indocyanine green (ICG) lymphography. Results: Animals in the treatment group showed a reduction in affected limb volume. Animals in the prevention group showed no increase in the affected limb volume. ICG fluoroscopy demonstrated lymph flow and formation of lymphatics toward healthy lymphatics. Conclusions: In the rat lymphedema model, implantation of BioBridge™ at the time of lymph node removal prevents the development of lymphedema. Treatment of established lymphedema with the BioBridge™ and ADSC reduces lymphedema. New lymphatic vessels are demonstrated by NIR fluoroscopy and MR lymphography. These findings have implications for the treatment of lymphedema in human subjects.

show abstract

Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane

Cited by 18 publications

References 25 publications

Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System

Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System

Breast cancer‐related lymphoedema: Risk factors and prediction model

Lymphatic regeneration after implantation of aligned nanofibrillar collagen scaffolds: Preliminary preclinical and clinical results

Contact Info

Product

Resources

About